Bayer AG (BAYN.DE) Expects Five Drugs to Enter Phase 3 in 2015
10/8/2013 7:14:31 AM
Bayer's recent positive run in drug development is set to continue with five candidates expected to hit phase III in 2015. The German pharma company has introduced five new products to market in recent years, including two expected blockbusters in the form of eye condition treatment Eylea and next-generation anticoagulant Xarelto, and expects to follow that with five products in oncology, cardiology and women's health. These candidates include finerenone (BAY 94-8862), a mineralocorticoid receptor antagonist which the company is developing as an oral treatment for chronic heart failure.
Help employers find you! Check out all the jobs and post your resume.